3190 completed, 581 recruiting, 491 terminated, 491 unknown. 5536 Phase 1, 1815 Phase 2.
Follow Nervous System Diseases: new trials by email Literature Review of Nervous System Diseases trials Research Report on Nervous System Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of TBN Tetramethylpyrazine nitrone (TBN) tablet / Placebo - Healthy | Phase 1 | Not yet recruiting | Guangzhou Magpie Pharmaceuticals Co., Ltd. | 16 | 2028-09-01 | 2026-09-11 |
| Device for Bladder Control for Men With SCI Noninvasive electrical stimulation device to improve bladder control - Neurogenic Bladder | Phase 1 / Phase 2 | Not yet recruiting | VA Office of Research and Development | 12 | 2028-06-01 | 2026-06-25 |
| Phase 1/2 Study Evaluating the Safety, PK/PD, and Clinical Activity of Oral JBI-778 in Patients With Brain Metastases, Leptomeningeal Disease, or Recurrent High Grade Glioma JBI-778 - Brain Metastases From Solid Tumors, Leptomeningeal Disease | Phase 1 / Phase 2 | Not yet recruiting | Jubilant Therapeutics Inc. | 113 | 2028-04-01 | 2026-08-07 |
| Psilocybin After Trauma Surgery for Pain Psilocybin (Usona Institute), Postoperative analgesia - Pain Management, Postoperative Pain | Phase 1 | Not yet recruiting | Trent Emerick | 70 | 2027-12-31 | 2026-08-06 |
| Magnesium Sulfate in Pediatric Burn Dressing Changes magnesium sulfate, Normal Saline (0.9% NaCl) - Pediatric Burns | Phase 1 | Not yet recruiting | Hennepin Healthcare Research Institute | 10 | 2027-12-01 | 2026-10-09 |
| Terazosin for Dementia With Lewy Bodies Terazosin Hydrochloride, Placebo - Dementia With Lewy Bodies | Phase 1 / Phase 2 | Not yet recruiting | Qiang Zhang | 40 | 2027-10-01 | 2026-03-12 |
| Evaluation of Donor-Derived B Cell Infusions in Patients With Amyotrophic Lateral Sclerosis (ALS) B cell infusion - ALS - Amyotrophic Lateral Sclerosis | Phase 1 | Not yet recruiting | Mark Poznansky | 10 | 2027-09-01 | 2026-09-24 |
| Combining Low Oxygen Therapy and an Adenosine A2a Receptor Antagonist to Improve Functional Mobility After Spinal Cord Injury Istradefylline, low oxygen therapy - Spinal Cord Injuries, Myelopathy | Phase 1 / Phase 2 | Not yet recruiting | Randy Trumbower, PT, PhD | 40 | 2027-09-01 | 2026-03-20 |
| First In Human Randomised Trial of Rincell-1 in Adults With a Cochlear Implant Otic neural progenitors, cochlear implantation - Sensorineural Hearing Loss, Presbyacusis | Phase 1 / Phase 2 | Not yet recruiting | Rinri Therapeutics | 20 | 2027-09-01 | 2026-10-01 |
| Neuronavigation-guided FUS-induced BBB Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and Tau Neuronavigation-guided single-element focused ultrasound transducer, Lumason, Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents - Alzheimer Disease, Early Onset | Phase 1 | Not yet recruiting | Columbia University | 6 | 2027-08-01 | 2026-05-13 |
| Fecal MicrobiotaTransplant for the Treatment of Parkinson's Disease Fecal Microbiota Transplant - Parkinson Disease | Phase 1 | Not yet recruiting | ProgenaBiome | 10 | 2027-07-01 | 2026-10-09 |
| H3K27M-specific Immune Effector Cells Targeting DMG/DIPG H3K27M-EIEs - Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2027-06-30 | 2026-10-30 |
| The FORCE Trial Pilot: Fish Oil-enriched Nutrition for Radiotherapy in Cancer of the hEad and Neck Nutrition counseling, Fresubin Supportan - Head &Amp;Amp; Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | Anna Arthur, PhD | 15 | 2027-06-01 | 2026-08-07 |
| Phase I/IIa Trial of scAAV1.tMCK.NTF3 for Treatment of CMT1A scAAV1.tMCK.NTF3 - Charcot-Marie-Tooth Neuropathy Type 1A | Phase 1 / Phase 2 | Withdrawn | Nationwide Children's Hospital | 2027-04-01 | 2026-07-29 | |
| Sustained Release Oral Formulation For Treatment Of Parkinsons Disease Formulation A, Formulation B, Formulation C - Healthy Volunteers | Phase 1 / Phase 2 | Not yet recruiting | University of Minnesota | 32 | 2027-04-01 | 2026-10-01 |
| Safety Study of XT-150 in Participants With ALS XT-150 - Amyotrophic Lateral Sclerosis (ALS) | Phase 1 | Not yet recruiting | Xalud Therapeutics, Inc. | 8 | 2027-03-01 | 2026-07-29 |
| A Clinical Trial of Iron Supplementation for Youth With ADHD and Restless Sleep Ferrous Sulfate, Placebo - ADHD, Sleep Problems | Phase 1 / Phase 2 | Not yet recruiting | Hugo W. Moser Research Institute at Kennedy Krieger, Inc. | 70 | 2027-03-01 | 2026-05-04 |
| A Basket Clinical Study to Assess Glycerol Tributyrate in Patients With Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like Episodes (MELAS) or Leber's Hereditary Optic Neuropathy-Plus (LHON-Plus) Glycerol Tributyrate - MELAS Syndrome, Lebers Hereditory Optic Neuropathy With Extra Ocular Symptoms (LHON-Plus) | Phase 1 / Phase 2 | Not yet recruiting | George Washington University | 24 | 2027-03-01 | 2026-10-05 |
| Evaluate the Efficacy and Safety of EN001 in Patients With Sarcopenia EN001, EN001 Placebo - Sarcopenia | Phase 1 / Phase 2 | Not yet recruiting | ENCell | 132 | 2027-03-01 | 2026-09-11 |
| Proactively Intervening On Early Cranial Nerve Injury As A Delayed Sequela Of Oropharyngeal Cancer: A Randomized Feasibility Clinical Trial For Pro-Habilitation (proNERVE RCT) Prednisone, Ajovy, Manual Therapy - Cranial Nerve Injury, Oropharyngeal Cancer | Phase 1 | Not yet recruiting | M.D. Anderson Cancer Center | 48 | 2027-03-01 | 2026-09-21 |
Showing 20 of 5536. Sign in to see all of them.
Brain Neoplasms (588) · Alzheimer Disease (558) · Parkinson Disease (433) · Glioblastoma (329) · Central Nervous System Neoplasms (286) · Stroke (282) · Glioma (249) · Multiple Sclerosis (249) · Astrocytoma (231) · Gliosarcoma (183) · Amyotrophic Lateral Sclerosis (172) · Oligodendroglioma (161) · Epilepsy (143) · Spinal Cord Injuries (142) · Ischemic Stroke (132)
Central Nervous System Diseases (3548) · Brain Diseases (3093) · Neurodegenerative Diseases (1523) · Pathological Conditions, Signs and Symptoms (1411) · Neoplasms (1045) · Neoplasms by Site (1020) · Mental Disorders (992) · Nervous System Neoplasms (958) · Signs and Symptoms (958) · Neurologic Manifestations (924) · Neuromuscular Diseases (879) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (833) · Genetic Diseases, Inborn (773) · Neoplasms by Histologic Type (771)
Temozolomide (99) · Radiotherapy (74) · Sodium Chloride (57) · Cyclophosphamide (45) · Saline Solution (45) · Bevacizumab (37) · Donepezil (37) · Radiosurgery (37) · Magnetic Resonance Spectroscopy (36) · eslicarbazepine acetate (31) · Carboplatin (30) · opicapone (30) · Filgrastim (29) · Irinotecan (29) · fludarabine (28)
National Cancer Institute (NCI) (127) · Bial - Portela C S.A. (76) · GlaxoSmithKline (76) · National Institute of Neurological Disorders and Stroke (NINDS) (64) · Biogen (54) · Pfizer (54) · Eli Lilly and Company (49) · Merck Sharp & Dohme LLC (48) · Johns Hopkins University (38) · M.D. Anderson Cancer Center (37) · AstraZeneca (36) · Duke University (35) · Mayo Clinic (33) · Wyeth is now a wholly owned subsidiary of Pfizer (33) · Stanford University (32)
United States (3168) · China (365) · United Kingdom (341) · Canada (330) · Australia (239) · France (227) · Germany (207) · Spain (171) · Netherlands (157) · South Korea (126) · Italy (117) · Belgium (106) · Japan (105) · Israel (85) · Sweden (75)
Danna Jennings, MD (12)
PMID 31072380, PMID 37624739, PMID 31420846, PMID 33175411, PMID 37171121, PMID 40680102, PMID 24524452, PMID 29480210, PMID 30741694, PMID 31127735, PMID 32250312, PMID 36463457, PMID 36602886, PMID 37539981, PMID 37996817, PMID 38489195, PMID 38588457, PMID 40739200, PMID 10816186, PMID 11927799, PMID 12119802, PMID 12542793, PMID 15117425, PMID 15738343, PMID 15864738, PMID 16030064, PMID 16614412, PMID 16896165, PMID 17351147, PMID 17562928, PMID 18323467, PMID 18342407, PMID 18713956, PMID 18787087, PMID 19717023, PMID 20734360, PMID 20876843, PMID 20937945, PMID 22163120, PMID 22338078, PMID 22415951, PMID 23300829, PMID 23377664, PMID 23463272, PMID 23545055, PMID 23860343, PMID 23982748, PMID 24412048, PMID 24759263, PMID 25133431
2023 (42), 2015 (27), 2019 (27), 2025 (27), 2014 (26), 2018 (24), 2017 (22), 2016 (19), U01CA081457 (15), P30CA033572 (12), UM1CA097452 (11), U01CA062475 (8), U01CA097452 (8), 2009 (7), U01CA137443 (7)